Science AI Journal
Medicine · Research topic

Open research questions in Bone Tumor Diagnosis and Treatments

266 gap statements mined from Bone Tumor Diagnosis and Treatments papers in our 7.9M-paper local library, which holds 1,777 papers on the topic — drawn mostly from each paper's own stated research gap, future-work, challenge and limitation notes, and its abstract. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one.

Choosing where to publish on Bone Tumor Diagnosis and Treatments? See the ranked Medicine journals.

What the literature leaves open

  • SEER lacks data on recurrence, functional outcomes, and disease-specific progression, limiting the ability to assess long-term disease control and patient-centered outcomes. Limited information on the center/geographic region patients received treatment in was available. Furthermore, the granularity of the data is limited given that data from the SEER Program is population- and not patient-level.

    Comparative analysis of pelvic/sacral versus vertebral chordomas in the US from 2000 to 2020 · 2026 · DOI

  • This pattern has not been well studied in the literature, complicating histological interpretation and necessitating GRM1 testing for diagnosis.

    Chondromyxoid fibroma with limited or no chondromyxoid stroma: A clinicopathological study of 3 cases · 2026 · DOI

  • The study detailed here provides further evidence of potential redox-related susceptibilities using a compound that targets IDH1 in vitro and in vivo efficacy in chordoma that warrant further investigation.

    Targeting chordoma via an isocitrate dehydrogenase-1-dependent susceptibility to redox metabolism · 2026 · DOI

  • Taken together, these data suggest that a binary R0/R1 classification is insufficient for risk stratification, and that margin width and the use of adjuvant radiotherapy should be recorded whenever possible.

    Risk factors for postoperative recurrence of sacral chordoma: an eleven-year single-centre retrospective study · 2026 · DOI

  • Future prospective studies are required to validate these findings.

    Percutaneous cryoablation of musculoskeletal tumours: the largest reported single-centre case series — outcomes, complications and subgroup analysis · 2026 · DOI

  • The available literature on maxillofacial ABCs is largely limited to isolated case reports and small case series. There is a need for more studies on the management of maxillofacial ABCs.

    Management of maxillofacial aneurysmal bone cysts: a single center experience · 2026 · DOI

  • In contrast, complex chromosomal alterations were lacking in 32 conventional giant cell tumors of bone tested (24 by karyotype, 7 by SNP array, 1 by DNA NGS), 3 atypical giant cell tumors of bone with isolated marked nuclear atypia (2 by karyotype, 1 by SNP array) and 3 metastasizing conventional giant cell tumors of bone (2 by DNA NGS, 1 by karyotype).

    Malignant Giant Cell Tumor of Bone · 2025 · DOI

  • These analyses confirmed the characteristic FOS rearrangement commonly observed in OB and revealed a novel fusion gene, FOS::FN1::FOS, which has not been reported previously.

    Pseudopapillary Osteoblastic Tumor With Psammomatous/Dot-Like Calcification of the Jawbone · 2025 · DOI

  • Notably, it should be kept in mind that KPGCT lacks metaplastic bone formation. Keratin immunostains highlight the diagnostic mononuclear cells. The genetic hallmark of KPGCT is an HMGA2– NCOR2 gene fusion. Surgery is the mainstay of treatment for localized KPGCT. Pexidartinib may be a promising treatment option for selected patients with advanced/metastatic disease.

    Keratin-Positive Giant Cell-Rich Tumor: A Review and Update · 2024 · DOI

  • While this mutation aids in GCTB identification, its utility in predicting prognosis remains unclear.

    Giant cell tumor of bone: exploring HtrA1 as a potential predictor of recurrence · 2026 · DOI

  • Future research should focus on characterizing atypical radiologic and histologic features, conducting long-term clinical follow-up, and performing detailed molecular profiling to further refine the classification and management of notochord-derived tumors.

    Atypical notochordal cell tumors: an alternative diagnosis when diagnostic criteria are not straightforward · 2026 · DOI

  • However, the degree of mineralization achieved varies between patients, and the biological factors influencing this variability remain poorly understood.

    An osteogenic microenvironment improves response during denosumab treatment in giant cell tumors of bone in the spine · 2026 · DOI

  • Assessment of skeletal disease is limited by the use of different radiopharmaceuticals at baseline (FDG, 2004) and follow-up (NaF, 2023).

    Adult fibrous dysplasia/McCune–Albright syndrome with hypoparathyroidism: additional skeletal lesions and an unusual bone turnover profile · 2026 · DOI

  • Study subjects or cohorts overlap Study subjects have not been previously reported.

    Can bone tumor radiology reporting systems be used in children?: a validation study for Bone-RADS and OT-RADS in MRI in the evaluation of solitary bone tumors · 2026 · DOI

  • Further case series and longer follow-up are warranted to establish durability and safety.

    Transoral Sclerotherapy with Etoxysclerol for Aneurysmal Bone Cyst of the First Cervical Vertebra · 2026 · DOI

  • Larger prospective comparative studies are warranted to establish its efficacy relative to existing minimally invasive treatment options.

    Minimally Invasive Treatment of Aneurysmal Bone Cysts Utilizing a Modified Sclerograft Technique · 2026 · DOI

  • Previous studies have demonstrated the efficacy of zoledronic acid in osteoid osteoma, but pediatric data remain scarce.

    Bisphosphonates in osteoid osteoma with difficult location in children · 2026 · DOI

  • Immune checkpoint blockade has produced occasional durable responses, particularly in dedifferentiated chondrosarcoma, but clinical activity is inconsistent and validated treatment-selection biomarkers are lacking.

    Immune escape biomarkers in chondrosarcoma: implications for PD-1/PD-L1 blockade and precision combination therapy · 2026 · DOI

  • While some recommend the use of grafts or substitutes, their role remains uncertain.

    Surgical Treatment of Enchondromas of the Hand: Our Experience in Curettage Only and Early Mobilization · 2025 · DOI

  • Future studies are needed to validate this technique in larger cohorts and to establish standardized protocols.

    Full-endoscopic pedicle-based approach for resection of osteoid osteoma in the lumbar spine: a case report and review of current literature · 2025 · DOI

  • The surgical treatment strategy for enchondroma, particularly in pathologic fractures, remains unclear.

    Early Single-Stage Curettage and Autogenous Bone Grafting for Enchondroma in the Hand with Minimally Displaced Pathologic Fracture · 2025 · DOI

  • Histology was informative but did not account for model performance by itself: discrimination remained substantial after histology was removed and within the ICD-O-3 9220/3 chondrosarcoma NOS subgroup.

    Postdiagnostic pretreatment risk stratification for chondrosarcoma survival using routinely available registry variables: a SEER-based temporal validation study · 2026 · DOI

  • The exact malignant transformation of craniofacial fibrous dysplasia is difficult to estimate; until now, few reports have been mentioned in the literature.

    A Rare Case of Mandibular Chondrosarcoma Arising from Fibrous Dysplasia · 2025 · DOI

  • Anorganic bone mineral/P-15 (ABM/P-15) bone grafts provide an osteoconductive mineral scaffold with a synthetic collagen-mimetic peptide surface, but their use in oncologic cervical spine reconstruction remains sparsely described.

    ABM/P-15-enhanced bone graft in oncologic cervical spine reconstruction: two case reports and narrative discussion · 2026 · DOI

  • Strengths and limitations of this studyO_LIThe study uses a federated approach based on the Observational Health Data Sciences and Informatics (OHDSI) framework and the OMOP Common Data Model, enabling standardized and reproducible analyses across institutions and countries while preserving data privacy.

    MAScINSIGHT: A Real-World Data Study to Deepen Knowledge and Management of McCune-Albright Syndrome - Study Protocol for an Observational Study within OHDSI · 2026 · DOI

Most-cited papers in Bone Tumor Diagnosis and Treatments

Most recent work

Find a gap in your own Bone Tumor Diagnosis and Treatments sub-topic

This page shows what the Bone Tumor Diagnosis and Treatments literature already flags as unresolved. To narrow it to your specific question, search the Research Gap Finder: the search is free with a free account and lists the papers closest to your topic first. Unlocking that topic (50 credits, charged once) fills the comparison table from our 7.9M-paper local library and writes the gaps from its rows.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
4,869 open questions
Dementia and Cognitive Impairment Research
3,297 open questions
Cancer Immunotherapy and Biomarkers
2,687 open questions
Liver Disease Diagnosis and Treatment
2,481 open questions
Substance Abuse Treatment and Outcomes
2,366 open questions
Sports Performance and Training
2,276 open questions
Mosquito-borne diseases and control
2,124 open questions
Parkinson's Disease Mechanisms and Treatments
2,117 open questions
Open questions raised by papers listed on this page include: (1) This pattern has not been well studied in the literature, complicating histological interpretation and necessitating GRM1 testing for diagnosis (“Chondromyxoid fibroma with limited or no chondromyxoid stroma: A…”, 2026); (2) There is a need for more studies on the management of maxillofacial ABCs (“Management of maxillofacial aneurysmal bone cysts: a single center experience”, 2026); (3) While this mutation aids in GCTB identification, its utility in predicting prognosis remains unclear (“Giant cell tumor of bone: exploring HtrA1 as a potential predictor of recurrence”, 2026); (4) The degree of mineralization achieved varies between patients, and the biological factors influencing this variability remain poorly understood (“An osteogenic microenvironment improves response during denosumab treatment in…”, 2026); (5) Further case series and longer follow-up are warranted to establish durability and safety (“Transoral Sclerotherapy with Etoxysclerol for Aneurysmal Bone Cyst of the First…”, 2026). 266 gap statements have been mined from Bone Tumor Diagnosis and Treatments papers in our 7.9M-paper local library, which holds 1,777 papers on the topic; the gaps come from whichever of those papers state one. They are mostly the research gaps the authors state and the papers' abstracts, plus future-work, limitations and challenges passages. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 1,100,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? Acceptance odds for top, mid and open/emerging journals, in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck for prior publication across 7 sources and our local library.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

How Pre-Check worksHow AI Review works

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.